



Early Detection of Cancer and Its Recurrence – Technologies and Biomarkers to Enhance Clinical Translation

Guest Editor:

Dr. Rajan P. Kulkarni

Department of Dermatology,
Oregon Health & Science
University, Portland, OR 97239,
USA

Deadline for manuscript
submissions:

closed (31 May 2023)

Message from the Guest Editor

Early detection of cancer and earlier detection of its recurrence is of paramount importance to improve overall outcomes. Here we are interested not only in the biology and biomarkers related to earlier detection (including both circulating and tumor-specific markers) but also in advancing technologies to assist with translating these findings to clinical settings. In addition, many novel ideas fail to have clinical uptake for various reasons.

Articles of interest will thus span from technological improvements and advancements that may make the translational process to clinical applicability faster, easier, and/or less costly to specific markers or panels of markers that help to predict the presence of cancer or signify a change in the tumor behavior. In addition, articles that deal with prediction of treatment resistance (either prior to starting initial treatment or while on treatment) are also welcome, with emphasis on immunotherapies. Of special interest are findings that have applicability towards several cancers (multi-cancer or pan-cancer), though studies that are focused on single cancer types are also welcomed.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic
Oncology and Reproductive
Medicine, The University of Texas
MD Anderson Cancer Center,
Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)

Contact Us

Cancers Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/cancers
cancers@mdpi.com
[X@Cancers_MDPI](https://twitter.com/Cancers_MDPI)